Ryan M. Kemper

Ryan M. Kemper

Auto-generated profile, based on publicly available information

Ryan M. Kemper

Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina Chapel Hill NC USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
TDTaylor Dennison
Taylor Dennison
HHHillary Heiling
Hillary Heiling
ADAllison Deal
Allison Deal
KBKelly Brunk
Kelly Brunk
RKRyan Kemper
Ryan Kemper
AFAimee Faso
Aimee Faso
Palbociclib is a small-molecule cyclin-dependent kinase 4/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Patient-specific factors impacting dose reductions or discontinuations are unknown. The primary objective was to evaluate the association of age (<60 vs. ≥60 years) with palbociclib dose reductions or discontinuations secondary to neutropenia. This single-center, retrospective chart review included hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer patients ≥18 years treated with palbociclib between April 2015 and May 2020. Patients <60 years at the time of palbociclib initiation were in the younger group and patients ≥60 years were in the older group. Among the 107 patients included, younger patients were less likely than older patients to have a palbociclib starting dose <125 mg (0% vs. 11.9%, p = 0.02). Differences in palbociclib dose reductions or treatment discontinuations secondary to neutropenia were not detected (35.4% vs. 42.4%, p = 0.55). Neither the total number of palbociclib dose reductions (none: 54.2% vs. 49.1%, one: 33.3% vs. 42.4%, two: 12.5% vs. 8.5%, p = 0.61), nor the final dose of palbociclib (125 mg: 54.2% vs. 40.7%, 100 mg: 29.2% vs. 27.1%, 75 mg: 16.7% vs. 32.2%, p = 0.17) differed between younger and older patients. Age (<60 vs. ≥60 years) was not associated with the rate of palbociclib dose reductions or discontinuations secondary to neutropenia. Older (≥60 years) patients were more likely to start palbociclib at lower doses which may impact neutropenia and non-neutropenic intolerance.



9 June 2023 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
TDTyler C. Dunlap
Tyler C. Dunlap
DWDaniel L. Weiner
Daniel L. Weiner
RKRyan M. Kemper
Ryan M. Kemper
MKMiramar Kardouh
Miramar Kardouh
SDSusanna C. DeVane
Susanna C. DeVane
DCDaniel Crona
Daniel Crona

11 July 2024 in European Journal of Haematology
Verified
Journal Article
Closed access
MLMandee Lines
Mandee Lines
RKRyan M. Kemper
Ryan M. Kemper
JWJordan Wallace
Jordan Wallace
TAThomas B Alexander
Thomas B Alexander
CECarmen Echols
Carmen Echols
KPKynlon Phillips
Kynlon Phillips